Repositioning Candidate Details
| Candidate ID: | R0281 |
| Source ID: | DB00963 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Bromfenac |
| Synonyms: | |
| Molecular Formula: | C15H12BrNO3 |
| SMILES: | NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 |
| Structure: |
|
| DrugBank Description: | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool to optimize surgical outcomes. |
| CAS Number: | 91714-94-2 |
| Molecular Weight: | 334.165 |
| DrugBank Indication: | For the treatment of postoperative inflammation in patients who have undergone cataract extraction. |
| DrugBank Pharmacology: | Bromfenac ophthalmic solution is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. |
| DrugBank MoA: | The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. |
| Targets: | Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|